UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN¿DIRECTED CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA SZ Usmani; JG Berdeja; A Jakubowiak; M Agha; AD Cohen; D Madduri; P Hari; T Yeh; Y Olyslager; A Banerjee; CC Jackson; A Allred; E Zudaire; W Deraedt; X Wu; L Pacaud; M Akram; Y Lin; T Martin; S Jagannath;

EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER 1¿3 PRIOR LINES OF THERAPY: CARTITUDE-2 PHASE 2 STUDY ME Agha; AD Cohen; D Madduri; YC Cohen; M Delforge; J Hillengass; H Goldschmidt; K Weisel; M Raab; C Scheid; JM Schecter; KC Braganca; H Varsos; L Wang; M Vogel; MJ Carrasco-Alfonso; M Akram; X Wu; T Nesheiwat; H Einsele;

CILTACABTAGENE AUTOLEUCEL VS STANDARD OF CARE IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: PHASE 3 CARTITUDE-4 SUBGROUP ANALYSIS BY CYTOGENETIC RISK R Mina; B Dhakal; J San-Miguel; N Lendvai; M Vogel; K Li; D Chen; N Patel; H Einsele; J Martinez-Lopez;